Brian Marckx von Zacks gestern auf insgesamt 22 Seiten zum Ausblick und den Katalysatoren für CTSO. Fair Value nach deren DCF-Modell bei 13,75 USD.
„More importantly, there is little doubt in our minds that utilization is begetting more utilization and the reasons likely almost universally relate to the ever-growing amount of evidence supporting the utility (i.e. safety and effectiveness) of CytoSorb in various critical care applications. As many more of these experiences from single-patient case studies to relatively large, formal, randomized controlled studies are now making their way into published manuscripts in leading industry journals, we think this will bode exceptionally well for generating additional awareness of CytoSorb and translating into greater adoption and utilization.“